Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-04-05, Stock:NVS, The news for the past five days is as follows:
2018-03-28: NEWS1: How Did Novartis’s Gleevec, Tasigna, and Sandostatin Perform in 4Q17?.NEWS2: How Did Novartis’s Gleevec, Tasigna, and Sandostatin Perform in 4Q17?.NEWS3: How Novartis’s Oncology Segment Drugs Are Performing.NEWS4: How Did Novartis Perform in 4Q17 and Full-Year 2017?.NEWS5: Company News For Mar 28, 2018.NEWS6: Company News For Mar 28, 2018.NEWS7: European ADRs Move Higher in Wednesday Trading.NEWS8: European ADRs Move Higher in Wednesday Trading.NEWS9: Glaxo (GSK) Buys Novartis' Stake in Consumer Healthcare JV.NEWS10: Glaxo (GSK) Buys Novartis' Stake in Consumer Healthcare JV.NEWS11: Company News For Mar 28, 2018.NEWS12: Health care trumps terrorism, gun violence concerns for Americans.NEWS13: In Battle To Cut Drug Prices, Outcome-Based Pricing Carries Big Risks For Biopharma.NEWS14: Glaxo (GSK) Buys Novartis&apos; Stake in Consumer Healthcare JV.NEWS15: The Swiss Stock Market Jumped On Strength Of Defensive Heavyweights.NEWS16: The Swiss Stock Market Jumped On Strength Of Defensive Heavyweights.NEWS17: Novartis AG -- Moody's: Novartis's sale of joint venture stake could be credit positive, but uncertainty around use of proceeds and financial policies persist.NEWS18: Biotech Stocks Facing FDA Decision In April.NEWS19: Biotech Stocks Facing FDA Decision In April.NEWS20: [$$] GSK Buys Novartis’s Stake in Health-Care Unit for $13 Billion.NEWS21: [$$] Inside story about the past few weeks of dealmaking at GSK.
2018-03-29: NEWS1: Novartis Likely Delayed In Launching Copycat Of Amgen Blockbuster.NEWS2: Novartis Likely Delayed In Launching Copycat Of Amgen Blockbuster.NEWS3: What’s Merck’s Valuation in March 2018?.NEWS4: What’s Merck’s Valuation in March 2018?.NEWS5: Exclusive: Penn patient shares the story of her CAR-T cell therapy journey.NEWS6: Exclusive: Penn patient shares the story of her CAR-T cell therapy journey.NEWS7: How Is Novartis’s Cosentyx Positioned after 4Q17?.NEWS8: How Novartis’s Ophthalmology Business Performed in 2017.NEWS9: How Novartis’s Ophthalmology Business Performed in 2017.NEWS10: The Swiss Stock Market Fell On Pharma Weakness.NEWS11: The Swiss Stock Market Fell On Pharma Weakness.NEWS12: How Merck Stock Has Performed Recently.NEWS13: How Merck Stock Has Performed Recently.NEWS14: How Did Novartis’s Affinitor, Exjade, and Tafinlar+Mekinist Perform in 2017?.NEWS15: How Did Novartis’s Affinitor, Exjade, and Tafinlar+Mekinist Perform in 2017?.
2018-04-02: NEWS1: Puma's Shares Fall This Year Post a Solid 2017: Here's Why.NEWS2: Puma's Shares Fall This Year Post a Solid 2017: Here's Why.NEWS3: On World Autism Awareness Day, A Look At Biotech Firms With Potential Treatments In The Pipeline.NEWS4: Shire's Stock Continues to Rise as Takeda Sets Eyes On it.NEWS5: Shire's Stock Continues to Rise as Takeda Sets Eyes On it.NEWS6: VEA, EFU: Big ETF Inflows.NEWS7: VEA, EFU: Big ETF Inflows.NEWS8: How Novartis’s Alcon Performed in 4Q17 and Fiscal 2017.NEWS9: How Novartis’s Alcon Performed in 4Q17 and Fiscal 2017.NEWS10: How Did Sandoz Perform in 4Q17 and Fiscal 2017?.NEWS11: How Did Sandoz Perform in 4Q17 and Fiscal 2017?.NEWS12: How Novartis’s Cardio-Metabolic and Neuroscience Segments Performed.NEWS13: How Novartis’s Cardio-Metabolic and Neuroscience Segments Performed.NEWS14: Analysts’ Recommendations for Bristol-Myers Squibb in March 2018.NEWS15: Analysts’ Recommendations for Bristol-Myers Squibb in March 2018.
2018-04-03: NEWS1: CASI Makes Case For Hope, MYND On Track, URGN Sprints, No Stopping INNT.NEWS2: CASI Makes Case For Hope, MYND On Track, URGN Sprints, No Stopping INNT.NEWS3: Pfizer Takes On Gilead, Novartis With New Deal In Cancer Drugs.NEWS4: Pfizer Takes On Gilead, Novartis With New Deal In Cancer Drugs.NEWS5: Why GlaxoSmithKline Stock Rose in the Week Ended March 29.NEWS6: Why GlaxoSmithKline Stock Rose in the Week Ended March 29.NEWS7: Amgen's (AMGN) Xgeva Gets EU Approval for Expanded Label.NEWS8: Amgen's (AMGN) Xgeva Gets EU Approval for Expanded Label.NEWS9: Better Buy: Acadia Pharmaceuticals vs. Eli Lilly.NEWS10: Better Buy: Acadia Pharmaceuticals vs. Eli Lilly.NEWS11: The Swiss Stock Market Begins The Week With A Substantial Loss.NEWS12: The Swiss Stock Market Begins The Week With A Substantial Loss.NEWS13: What Analysts Recommend for Novartis in March 2018.NEWS14: What Analysts Recommend for Novartis in March 2018.NEWS15: Will These Drugs Reach Blockbuster Status?.NEWS16: Will These Drugs Reach Blockbuster Status?.
2018-04-04: NEWS1: Rigel (RIGL) Sinks on Failure of Mid-Stage Study on Lead Drug.NEWS2: Rigel (RIGL) Sinks on Failure of Mid-Stage Study on Lead Drug.NEWS3: GlaxoSmithKline's Horlicks Up for Grabs: Who Will Snap It Up?.NEWS4: GlaxoSmithKline's Horlicks Up for Grabs: Who Will Snap It Up?.NEWS5: Pfizer Inks New CAR-T Deal, In Talks With P&G for Unit Sale.NEWS6: Pfizer Inks New CAR-T Deal, In Talks With P&G for Unit Sale.NEWS7: Johnson & Johnson’s Quarterly Revenue Trend in 2017.NEWS8: Today’s Research Reports on Stocks to Watch: UroGen Pharma and Novartis.NEWS9: Novartis Announces JAMA Cardiology Publication Of Data.NEWS10: Novartis Announces JAMA Cardiology Publication Of Data.

Answer: Rise